Iheanacho Emeruwa, MD
Pulmonary Disease · Los Angeles, CANPI 1013335355
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,500 of the $3,739 with a category attached, or 66.9%. Amgen accounts for 66.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,612 and has fallen 84.6% since, to $401 in 2024.
Across 17 payments — averaging $219.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- La Jolla Pharmaceutical Company$521
- Abbott$239
- Sanofi$138
- Eisai Inc.$125
- Abiomed$79
- plus $138 from 3 others
What the payments were for
- Consulting fees$2,50067%
- Food & beverage$1,23933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $2,500 |
| La Jolla Pharmaceutical Company | 4 | $521 |
| Abbott | 3 | $239 |
| Sanofi | 1 | $138 |
| Eisai Inc. | 1 | $125 |
| Abiomed | 1 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $66 |
| Fresenius USA Marketing, Inc. | 1 | $57 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,739 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,096 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,046 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $252 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.